Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Usage Information

SOCS2 negatively regulates growth hormone action in vitro and in vivo
Christopher J. Greenhalgh, Elizabeth Rico-Bautista, Mattias Lorentzon, Anne L. Thaus, Phillip O. Morgan, Tracy A. Willson, Panagiota Zervoudakis, Donald Metcalf, Ian Street, Nicos A. Nicola, Andrew D. Nash, Louis J. Fabri, Gunnar Norstedt, Claes Ohlsson, Amilcar Flores-Morales, Warren S. Alexander, Douglas J. Hilton
Christopher J. Greenhalgh, Elizabeth Rico-Bautista, Mattias Lorentzon, Anne L. Thaus, Phillip O. Morgan, Tracy A. Willson, Panagiota Zervoudakis, Donald Metcalf, Ian Street, Nicos A. Nicola, Andrew D. Nash, Louis J. Fabri, Gunnar Norstedt, Claes Ohlsson, Amilcar Flores-Morales, Warren S. Alexander, Douglas J. Hilton
View: Text | PDF
Article Endocrinology

SOCS2 negatively regulates growth hormone action in vitro and in vivo

  • Text
  • PDF
Abstract

Mice deficient in SOCS2 display an excessive growth phenotype characterized by a 30–50% increase in mature body size. Here we show that the SOCS2–/– phenotype is dependent upon the presence of endogenous growth hormone (GH) and that treatment with exogenous GH induced excessive growth in mice lacking both endogenous GH and SOCS2. This was reflected in terms of overall body weight, body and bone lengths, and the weight of internal organs and tissues. A heightened response to GH was also measured by examining GH-responsive genes expressed in the liver after exogenous GH administration. To further understand the link between SOCS2 and the GH-signaling cascade, we investigated the nature of these interactions using structure/function and biochemical interaction studies. Analysis of the 3 structural motifs of the SOCS2 molecule revealed that each plays a crucial role in SOCS2 function, with the conserved SOCS-box motif being essential for all inhibitory function. SOCS2 was found to bind 2 phosphorylated tyrosines on the GH receptor, and mutational analysis of these amino acids showed that both were essential for SOCS2 function. Together, the data provide clear evidence that SOCS2 is a negative regulator of GH signaling.

Authors

Christopher J. Greenhalgh, Elizabeth Rico-Bautista, Mattias Lorentzon, Anne L. Thaus, Phillip O. Morgan, Tracy A. Willson, Panagiota Zervoudakis, Donald Metcalf, Ian Street, Nicos A. Nicola, Andrew D. Nash, Louis J. Fabri, Gunnar Norstedt, Claes Ohlsson, Amilcar Flores-Morales, Warren S. Alexander, Douglas J. Hilton

×

Usage data is cumulative from May 2025 through May 2026.

Usage JCI PMC
Text version 1,413 121
PDF 190 40
Figure 574 30
Table 67 0
Supplemental data 79 4
Citation downloads 122 0
Totals 2,445 195
Total Views 2,640
(Click and drag on plot area to zoom in. Click legend items above to toggle)

Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.

Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.

Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts